# RIT1

Source: https://onco.cc/targets/rit1/  
OnCo record `rit1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RIT1 (GTP-binding protein Rit1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Non-small-cell lung cancer.

## Summary

Plays a crucial role in coupling nerve growth factor (NGF) stimulation to the activation of both EPHB2 and MAPK14 signalling pathways and in NGF-dependent neuronal differentiation. Involved in ELK1 transactivation through the Ras-MAPK signalling cascade that mediates a wide variety of cellular functions, including cell proliferation, survival, and differentiation. Recognised by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.

CIViC holds 14 clinical evidence items and 0 assertions across 8 variants, naming Selumetinib and Pictilisib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: Ras like without CAAX 1; GTP-binding protein Rit1; ROC1; MGC125864; MGC125865
- Tags: cancer-genes-wave
- Symbol: RIT1
- Class: enzyme
- Biology: Plays a crucial role in coupling nerve growth factor (NGF) stimulation to the activation of both EPHB2 and MAPK14 signalling pathways and in NGF-dependent neuronal differentiation. Involved in ELK1 transactivation through the Ras-MAPK signalling cascade that mediates a wide variety of cellular functions, including cell proliferation, survival, and differentiation. Recognised by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. Location: Cell membrane (UniProt). Locus 1q22 (HGNC).
- Where found: Endometrial cancer: CIViC evidence names this disease; Non-small-cell lung cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 14 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:10023: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10023
- UniProt Q92963: https://www.uniprot.org/uniprotkb/Q92963/entry
- NCBI Gene 6016: https://www.ncbi.nlm.nih.gov/gene/6016
- Ensembl ENSG00000143622: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143622

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/rit1.json